KROS
Keros Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$10.61-0.28%
Price as of Jul 20, 2026
KROS growth
Keros Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -84.5%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- -1.7%
- EBITDA
- +92.7%
- EPS
- -37.7%
Three-year CAGR
- Revenue
- +3920.3%
- EBITDA
- +150.3%
- EBIT
- +133.5%
- Net income
- +146.4%
- EPS
- +146.8%
- Free cash flow
- +165.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.